Research on Tenofovir (Viread)
HIV Treatment Research
- New Tenofovir Prodrug (TAF): One Study Whose Impact Will Last Well Beyond CROI 2013 (March 14, 2013)
In The 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), from TheBodyPRO.com
- New Pro-Drug Tenofovir Alafenamide Appears Equally Effective but Better Tolerated (March 7, 2013)
From aidsmap.com
 New Tenofovir Prodrug Shows Potency, Plus Better Kidney and Bone Safety Than Current Formulation (March 7, 2013)
In The 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), from TheBodyPRO.com
- In HIV, Old Drug Is New Again (March 6, 2013)
From MedPage Today
- New Tenofovir Alafenamide Looks Easier on Kidneys (Video) (March 6, 2013)
From HIVandHepatitis.com
- New Tenofovir Prodrug Virologically Equivalent to TDF -- and Easier on Kidneys and Bone (March 5, 2013)
From National AIDS Treatment Advocacy Project
 The Hot List: Top 10 HIV Conference Articles of 2012 on TheBodyPRO.com (December 18, 2012)
From TheBodyPRO.com
 Building a Better Tenofovir: Oral Prodrug GS-7340 Outperforms "Old" Tenofovir, Research Finds (October 26, 2012)
In The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) , from TheBodyPRO.com
- Switching to Tenofovir in ART Regimen Suppresses Hepatitis B in HIV/HBV Coinfected (September 14, 2012)
From HIVandHepatitis.com
- Proteinuria as a Potential Early Marker of Tenofovir-Related Renal Toxicity (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
VIEW ALL ARTICLES
|
Advertisement
|
Email
Glossary
